Methods for promoting hair growth, and needling devices for use with such methods, are provided. Certain of the methods include disruption of the skin with a powered needling device, followed by an administration of a hair growth-promoting agent.

The present invention relates to a composition for preventing hair loss or promoting hair growth, comprising ginsenoside Rg4 or a mixture of ginsenosides Rg2, Rg4, Rg6, and Rh1 as an active ingredient. Treatment with ginsenoside Rg4 or the mixture of ginsenosides Rg2, Rg4, Rg6, and Rh1 in human hair follicle dermal papilla cells exhibits a desirable effect of forming three-dimensional spheres capable of inducing hair follicle formation and growth and increasing the size thereof, exhibits a desirable effect of activating Wnt/β-catenin signaling, which is important for hair follicle cell activation and regeneration, and exhibits a desirable effect of increasing the expression levels of ALPL, VCAN, BMP2, and FGF7 genes, which are important for hair follicle formation and growth. Thus, ginsenoside Rg4 or the mixture of ginsenosides Rg2, Rg4, Rg6, and Rh1 can be usefully utilized as a composition for preventing hair loss and promoting hair growth.

The present invention relates to a composition for preventing hair loss or promoting hair growth, comprising ginsenoside Rg4 or a mixture of ginsenosides Rg2, Rg4, Rg6, and Rh1 as an active ingredient. Treatment with ginsenoside Rg4 or the mixture of ginsenosides Rg2, Rg4, Rg6, and Rh1 in human hair follicle dermal papilla cells exhibits a desirable effect of forming three-dimensional spheres capable of inducing hair follicle formation and growth and increasing the size thereof, exhibits a desirable effect of activating Wnt/β-catenin signaling, which is important for hair follicle cell activation and regeneration, and exhibits a desirable effect of increasing the expression levels of ALPL, VCAN, BMP2, and FGF7 genes, which are important for hair follicle formation and growth. Thus, ginsenoside Rg4 or the mixture of ginsenosides Rg2, Rg4, Rg6, and Rh1 can be usefully utilized as a composition for preventing hair loss and promoting hair growth.

A compound compound having the structure:

##STR00001##

or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A, A′ and A″ are independently O, C═O, C—R′ or N—R″, where R′ and R″ may independently be H, amino, —NR.sub.7COR.sub.6, COR.sup.6, —CONR.sub.7R.sub.8, C.sub.1-C.sub.6 alkyl, or hydroxy(C.sub.1-C.sub.6 alkyl), and R″ may be present or absent, and is present where the rules of valency permit, and where not more than one of A, A′ and A″ is O or C═O; R.sub.0 and R are independently H, Br, Cl, F, or C.sub.1-C.sub.6 alkyl; R.sub.1 is H, C.sub.1-C.sub.6 alkyl, or hydroxy(C.sub.1-C.sub.6 alkyl); R.sub.2 is selected from the group consisting of H, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, hydroxy(C.sub.1-C.sub.6 alkyl), phenyl(C.sub.1-C.sub.6 alkyl), formyl, heteroaryl, heterocyclic, —COR.sub.6, —OCOR.sub.6, —COOR.sub.6, —NR.sub.7COR.sub.6, —CONR.sub.7R.sub.8, and —(CH.sub.2).sub.n—W, where W is cyano, hydroxy, C.sub.3-C.sub.8 cycloalkyl, —SO.sub.2NR.sub.7R.sub.8, and —SO.sub.2—R.sub.9, where R.sub.9 is C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.8 cycloalkyl, heteroaryl, or heterocyclic; wherein each of said alkyl, cycloalkyl, heterocyclic, or heteroaryl may be unsubstituted or substituted by halo, cyano, hydroxy, or C.sub.1-C.sub.6 alkyl; X is C—R.sub.3 or N, where R.sub.3 may be H or C.sub.1-C.sub.6 alkyl; R.sub.4 and R.sub.5 are independently H, amino, C.sub.1-C.sub.6 alkyl, or hydroxy(C.sub.1-C.sub.6 alkyl); R.sub.6, R.sub.7 and R.sub.8 are each independently H, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.4 alkoxy(C.sub.1-C.sub.6 alkyl), or C.sub.3-C.sub.8 cycloalkyl, said C.sub.1-C.sub.6 alkyl is optionally substituted by halo, CN or hydroxy; or, R.sub.7 and R.sub.8 together with the atom bonded thereto form a 5- or 6-membered ring, said ring being optionally substituted by halo, hydroxy, CN, or C.sub.1-C.sub.6 alkyl; and, n is 0, 1, 2 or 3. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.

The subject invention relates to novel soluble forms of planar ring structured organic compounds including flavonoids, and their production. The invention also includes the use of these novel formulations of planar ring structured organic compounds in the preparation of formulations and products. The invention also relates to a wide variety of applications of the formulations of the invention. The subject invention includes novel soluble forms and various formulations of flavonoids. Further, the invention includes novel methods of manufacturing the flavonoid formulations. The invention also relates to a wide variety of applications of the flavonoid formulations.

The present invention discloses a use of mitochondria to promote wound repair and/or healing. Specifically, when a certain amount of mitochondria or a composition containing a certain amount of mitochondria is administered to a wound, the effect of promoting wound repair or accelerating wound healing can be effectively achieved.

It is an object of the present invention to provide a new agent for the treatment of alopecia, the agent being not only effective and safe for, in particular, alopecia areata, androgenetic alopecia in a male, androgenetic alopecia in a female, female pattern alopecia, postpartum alopecia, seborrheic alopecia, alopecia pityroides, senile alopecia, cancer chemotherapy drug-induced alopecia, and alopecia due to radiation exposure, but also effective for a target having resistance to treatment with minoxidil or finasteride, there being no side effects such as an itching sensation, irritation, or feminization, and no contraindications, the agent suppressing dandruff or having a therapeutic effect for white hair, and the therapeutic effect for alopecia being maintained for a long period even when use of the agent is stopped. The solution means of the present invention is an agent for the treatment of alopecia containing as an active ingredient a C-type natriuretic peptide (CNP), a B-type natriuretic peptide (BNP), a derivative of these NPs, a chimeric peptide of these NPs, or a derivative of a chimeric peptide of these NPs.

The present disclosure relates to crystalline solid forms of a stimulator of soluble guanylate cyclase (sGC), Compound I: ##STR00001##
Also provided herein are methods for the preparation of these solid forms. The invention also relates to pharmaceutical formulations and dosage forms comprising these solid forms and their uses thereof, alone or in combination with one or more additional agents, for treating and/or preventing various diseases or disorders; these diseases or disorders are ones that may benefit from sGC stimulation or from an increase in the concentration of nitric oxide (NO) and/or cyclic guanosine monophosphate (cGMP).

Methods and compositions for stimulating hair growth are disclosed. Compositions for stimulating hair growth include two or more of hyaluronic acid, osteopontin, and another CD44 binding ligand. Methods for stimulating hair growth include administering such composition into the skin of a patient.

The present invention relates to the preparation of 9-deoxo-36,37-dihydro-prolylFK506, 9-deoxo-31-O-demethyl-36,37-dihydro-prolylFK506, 9-deoxo-prolylFK520 or 9-deoxo-31-O-demethyl-prolylFK520, which are novel compounds that can be utilized as the main ingredient of a composition for promoting hair growth, and the use thereof in promoting hair growth.